David Cozzolino, MD
Urology · Wilmington, DENPI 1144278722
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $961 and has fallen 89.4% since, to $102 in 2025. That places this record below the midpoint for urology clinicians in DE, where the typical reported total is $2,396.
Across 93 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$464
- Astellas Pharma US Inc$295
- Pfizer$236
- Sumitomo Pharma America, Inc.$226
- AbbVie$190
- Bayer$103
- plus $883 from 21 others
What the payments were for
- Food & beverage$2,30796%
- Education$894%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 1 | $464 |
| Astellas Pharma US Inc | 18 | $295 |
| Pfizer | 7 | $236 |
| Sumitomo Pharma America, Inc. | 9 | $226 |
| AbbVie(2 entities) | 9 | $190 |
| Bayer | 5 | $103 |
| Teleflex LLC | 4 | $91 |
| Boston Scientific | 5 | $85 |
| Tolmar, Inc. | 4 | $82 |
| Blue Earth Diagnostics | 3 | $77 |
| Merck | 3 | $62 |
| Myriad Genetic Laboratories, Inc. | 1 | $57 |
| Ferring Pharmaceuticals Inc. | 3 | $50 |
| Progenics Pharmaceuticals, Inc. | 2 | $47 |
| AstraZeneca | 3 | $45 |
| Johnson & Johnson | 2 | $44 |
| Procept Biorobotics Corporation | 2 | $37 |
| Antares Pharma, Inc. | 2 | $31 |
| Myovant Sciences Inc. | 2 | $31 |
| Coloplast | 1 | $24 |
| Accord Healthcare, Inc. | 1 | $23 |
| Acerus Pharmaceuticals Corporation | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Immunitybio, Inc. | 1 | $16 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$119
How this compares
$2,396 in reported general payments places this provider in the 50th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 25 | $443,039 |
| ErleadaApalutamide | 11 | $166,593 |
| MyrbetriqMirabegron | 72 | $74,116 |
| GemtesaVibegron | 53 | $54,586 |
| OrgovyxRelugolix | 18 | $50,029 |
| Tamsulosin Hcl | 702 | $13,999 |
| Silodosin | 28 | $4,229 |
| Finasteride | 140 | $2,988 |
| Oxybutynin Chloride ErOxybutynin Chloride | 59 | $2,707 |
| Potassium Citrate ErPotassium Citrate | 32 | $2,644 |
| Dutasteride | 56 | $2,371 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 101 | $2,272 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 190 | $2,102 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $1,411 |
| Solifenacin Succinate | 20 | $1,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $295 | $517,15597 claims |
| Johnson & JohnsonErleada | $44 | $166,59311 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $226 | $104,61571 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 33 urology providers in Delaware.
Other urology in Wilmington
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Thomas DesperitoWilmington$7K
- Bruce BengeWilmington$5K
- Alice WangWilmington$4K
- Keara DecotiisWilmington$3K
- Mohamed IsmailWilmington$3K
- Mona YezdaniWilmington$2K
- Steven TerranovaWilmington$2K
- Andrew GlickWilmington$748
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.